AbbVie’s Humira tops the list, according to data compiled by EvaluatePharma.
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn’t stopped contenders such as Roche’s emicizumab.
When discussing the nation’s ability to stomach orphan drug costs, an analyst has called the price tag “the straw that breaks the camel’s back.”